<DOC>
	<DOC>NCT01340976</DOC>
	<brief_summary>This study will evaluate the safety LY2787106 in participants with cancer and anemia. It will also evaluate when LY2787106 can improve anemia. This study has two parts: Part A is a dose escalation evaluation. Part B is an evaluation of LY2787106 at a defined dose given with and without iron supplementation.</brief_summary>
	<brief_title>A Phase 1 Study of LY2787106 in Cancer and Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Have histological or cytological evidence of nonmyeloid cancer (solid tumors, lymphomas or multiple myeloma) that is metastatic and/or incurable Have been treated with at least one systemic (oral, intravenous, or subcutaneous) anticancer therapy or regimen Have a hemoglobin of less than or equal to 11 g/dL Have a hepcidin level of greater than or equal to 5 ng/mL Have given written informed consent prior to any studyspecific procedures Have adequate hematologic, hepatic, and renal organ function Have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2 Available for the duration of the study and willing to follow study procedures If male or female with reproductive potential: Must agree to use medically approved contraception during the trial and for 4 months following the last dose of study drug If female with child bearing potential: Have a negative serum pregnancy test Have an estimated life expectancy of greater than or equal to 12 weeks Have received treatment in the previous 21 days with, or have not recovered fully from, a drug that has not received regulatory approval for any indication Have received erythropoiesisstimulating agents in the previous 21 days or red blood cell transfusions in the previous 14 days, or in the investigator's opinion, likely to need red blood cell transfusion more frequently than every 21 days Have received parenteral iron supplementation within the prior 14 days Have a documented history of pure red cell aplasia, thalassemia major or sickle cell disease Have a history of cirrhosis or major organ transplantation QTc greater than 470 msec Have evidence of clinically significant hemolysis or bleeding Have a clinically significant systemic infection within 14 days of enrollment Have a suspected or confirmed history of hemochromatosis. Have other serious preexisting medical conditions (left to the discretion of the investigator) Have symptomatic central nervous system malignancy or metastasis (screening not required) Have acute or chronic leukemia Are a female who is pregnant or lactating Have a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C (screening not required) Have received external beam radiotherapy to more than 25% of the bone marrow Have known clinically significant hypersensitivity to biologic agents Have received live vaccine(s) within 1 month of screening or with plans of doing that during the participation to the study Have a history of congestive heart failure with New York Heart Association (NYHA)Class greater than 2 (NYHA Class 1 and 2 are eligible), unstable angina or recent myocardial infarction (within 1 year prior to administration of study drug)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Cancer Related Anemia</keyword>
</DOC>